313 related articles for article (PubMed ID: 38764762)
1. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
Boldys A; Buldak L
World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
[TBL] [Abstract][Full Text] [Related]
2. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
[TBL] [Abstract][Full Text] [Related]
4. Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?
Tulone A; Pennisi G; Ciccioli C; Infantino G; La Mantia C; Cannella R; Mercurio F; Petta S
United European Gastroenterol J; 2024 Jun; 12(5):638-648. PubMed ID: 38659291
[TBL] [Abstract][Full Text] [Related]
5. The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum.
Vidal-Cevallos P; Sorroza-Martínez AP; Chávez-Tapia NC; Uribe M; Montalvo-Javé EE; Nuño-Lámbarri N
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673981
[TBL] [Abstract][Full Text] [Related]
6. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
7. Natural history of metabolic dysfunction-associated steatotic liver disease.
Lekakis V; Papatheodoridis GV
Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
Curr Obes Rep; 2024 May; ():. PubMed ID: 38809396
[TBL] [Abstract][Full Text] [Related]
9. The pathophysiology of MASLD: an immunometabolic perspective.
Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
[TBL] [Abstract][Full Text] [Related]
10. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
[TBL] [Abstract][Full Text] [Related]
12. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.
Jiang Y; Wu L; Zhu X; Bian H; Gao X; Xia M
Lipids Health Dis; 2024 Apr; 23(1):95. PubMed ID: 38566209
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
[TBL] [Abstract][Full Text] [Related]
14. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
Benedé-Ubieto R; Cubero FJ; Nevzorova YA
Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
[TBL] [Abstract][Full Text] [Related]
15. Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease.
Li Y; Qi P; Song SY; Wang Y; Wang H; Cao P; Liu Y; Wang Y
Biomed Pharmacother; 2024 May; 174():116585. PubMed ID: 38615611
[TBL] [Abstract][Full Text] [Related]
16. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
Loomba R; Wong VW
Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
Zeng J; Fan JG; Francque SM
United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
[TBL] [Abstract][Full Text] [Related]
18. Update in lean metabolic dysfunction-associated steatotic liver disease.
Sato-Espinoza K; Chotiprasidhi P; Huaman MR; Díaz-Ferrer J
World J Hepatol; 2024 Mar; 16(3):452-464. PubMed ID: 38577539
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
Aggeletopoulou I; Tsounis EP; Triantos C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
[TBL] [Abstract][Full Text] [Related]
20. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
Targher G; Byrne CD; Tilg H
Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]